title: [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
abstract: The levels of levofloxacin (LVFX) in the serum, sputum and lung tissue were measured by a high-performance liquid chromatography method, and the penetration ratio of LVFX into respiratory tissue was investigated. The subjects of this study were 23 patients under pulmonectomy or brochoscopy. LVFX at the dose of 200 mg was given orally and specimens were collected as follows; serum at 2, 3 and 5 hours after, sputum at 2 hours after, and lung tissue at 3 and 5 hours after the administration, respectively. The mean level of LVFX in lung tissue at 3 hours was 3.91 +/- 2.33 micrograms/g, and those in sputum and in serum at 2 hours were 0.71 +/- 0.63 and 2.08 +/- 1.01 micrograms/ml, respectively. A very strong correlation was demonstrated between the level of LVFX in lung tissue and that in serum (p < 0.0001), but correlation between those in sputum and in serum was not significant. The penetration ratio of LVFX into lung tissue was 217.2% and that into sputum was 4.05%. Based on the results of this study, the breakpoints (BPs) of LVFX for pneumonia and chronic respiratory tract infections were calculated to be 4 micrograms/ml and 1 microgram/ml, respectively. It was concluded that penetration of LVFX into lung tissue was satisfactory, and the tissue level of LVFX exceeded greatly the MIC90s against the typical pathogenic bacteria of respiratory tract infections. Taking the excellent BP for pneumonia, 4 micrograms/ml, into consideration, it was thought that LVFX is an effective antibacterial agent against pneumonia and other respiratory tract infections.
authors.affiliation: Department of Surgery II, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Fujita
authors.forename: T
authors.initials: T
authors.lastname: Miya
authors.forename: R
authors.initials: R
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Hirayama
authors.forename: H
authors.initials: H
authors.lastname: Isaka
authors.forename: Y
authors.initials: Y
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Koshiishi
authors.forename: T
authors.initials: T
authors.lastname: Goya
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008168:Lung / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000378:metabolism; D012463:Saliva / Q000737:chemistry; D013997:Time Factors
chemical_list: D064704:Levofloxacin; D015242:Ofloxacin